Now PlayingEP. 1 Delayed FDA Filing for Neratinib, Halting of Potential PSA-Screening Penalty, New CEO for ASCO, and More
November 18th, 2026Elticertinib Receives FDA Fast Track Designation in EGFR Exon 20–Mutated NSCLCThe FDA granted fast track designation to elticertinib for pretreated EGFR exon 20 insertion–mutated NSCLC.Read more
November 18th, 2026FDA Grants Breakthrough Therapy Designation to Daretabart for Newly Diagnosed High-Risk NeuroblastomaPhase 2 NB2012 data showed a 3-year event-free survival rate of 73.7% with daretabart plus induction chemotherapy.Read more
November 18th, 2026Longitudinal Community Training Helps Prepare Oncology Fellows for Their Future CareersDeepa Rangachari, MD, discusses community oncology training, goal-concordant mentorship, genomic fluency, and multidisciplinary care.Read more
November 18th, 2026Mayo Clinic Study Finds Some BRCA2 Gene Changes Carry Lower Breast Cancer Risk Mayo Clinic researchers identified BRCA2 variants linked to moderate breast cancer risk, potentially informing personalized screening and prevention.Read more
November 18th, 2026NATALEE, DeLLphi-305, INTerpath-001, and LITESPARK-012 Headline Key Oncology Data From ESMO 2026Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.Read more
November 18th, 2026Galinpepimut-S Improves OS in AML in Second or Later RemissionMaintenance galinpepimut-S extended overall survival in transplant-ineligible AML in second or later remission.Read more
November 18th, 2026Updated KANDLELIT-001 Data Show Durable Responses With Frontline Calderasib Plus Pembrolizumab in KRAS G12C–Mutated NSCLCLonger follow-up of KANDLELIT-001 supports frontline calderasib plus pembrolizumab in KRAS G12C–mutated metastatic non–small cell lung cancer.Read more
November 17th, 2026Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLCThe CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.Read more